French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed on Nasdaq, is focused on developing and delivering therapies against novel epigenetic targets for patients with different types of cancer. Through the deal, Ipsen gets access to Tazverik (tazemetostat), the […]
Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine manufacturing facility at its Canadian headquarters, Sanofi Pasteur, in Toronto. This development is aimed at bolstering the company’s operational capabilities in Canada and reaffirming its commitment to advancing global public […]